EHA 26: Major Readouts Later This Year for Several Large Market Opportunities

Research evidence excerpt

EHA 26: Major Readouts Later This Year for Several Large Market Opportunities

Biotechnology

Disc Medicine, Inc. (IRON)

EQUITY RESEARCH Company Update

June 15, 2026

EHA 26: Major Readouts Later This Year for Several Price: $67.99

Price Target: $125.00 Large Market Opportunities

Rating: Overweight

What Happened?

Key Statistics:

Symbol NASDAQ: IRON ●Disc Medicine hosted a conference call today, 6/15, to discuss updates

52-Week Range 40.00 - 99.50 from the pipeline portfolio, including those that were presented at

Market Cap 2,597.2 EHA.

ADV (3 mo) 465,608

Shares Out (M) 38.2 ●IRON is a Top Pick, and we believe the company has several

blockbuster drugs in mid-late stage development, of which the

Research Analysts: applications could potentially expand to other indications.

Kristen Kluska

212-915-1927 Selcodebart (DISC-0974): High Response Rates Could Translate to A High Kristen.Kluska@cantor.com

Commercial Opportunity. Ayan Hussein, PhD

212-915-1122 ●The RALLY-MF data from DISC-0974 (anti-hemojuvelin antibody) in MF Ayan.Hussein@cantor.com

anemia at EHA were largely in line with what we saw from the oral Ross Fladeland

212-915-1803 presentation at ASCO (link to Cantor note).

ross.fladeland@cantor.com

●To recap, impressive outcomes and response rates were observed

REV ($M) across diverse patient groups regardless of transfusion dependence

FYE Dec 2025A 2026E 2027E status, background therapies, etc.

1Q $0.0 $0.0A $0.0

2Q $0.0 $0.0E $0.0 ●The company reiterated their stance that this could be a blockbuster

3Q $0.0 $0.0E $8.5 market with JAK inhibitor sales accounting for $2B annually but also

4Q $0.0 $0.0E $19.7 emphasizing that these drugs don't treat anemia (and can make it

Year $0.0 $0.0E $28.2

worse), and that not all patients receive JAK inhibitors (meaning the